Merck Announces Presentation of Phase 2b Results for Investigational HIV-1 Therapy Islatravir (MK-8591) at IAS 2019
Dateline City:
KENILWORTH, N.J.
New Findings from Study Evaluating Islatravir in Combination with Doravirine versus DELSTRIGO™ (doravirine 100 mg/3TC 300 mg/tenofovir disoproxil fumarate 300 mg)
Company Plans to Initiate Phase 3 Trials
KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced the results from a Phase 2b clinical trial evaluating the efficacy, tolerability, and safety of islatravir (MK-8591), the company’s investigational nucleoside reverse transcriptase translocation inhibitor (NRTTI), for the treatment of HIV-1.
Language:
English
Contact:
Media:
Pamela Eisele
(267) 305-3558
Sarra S. Herzog
(201) 669-6570
Investors:
Teri Loxam
(908) 740-1986
Michael DeCarbo
(908) 740-1807
Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
@Merck
